title: Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
abstract: The 340B program, a drug discount program created by the US Congress, allows safety-net providers to access discounted drug pricing that helps low-income and vulnerable patients. This program has recently been the subject of significant discussions as to its potential implications. Herein we review the role of the 340B drug discount program and its relevance to recent trends in cancer care and to the access of safety-net providers and vulnerable patients to much-needed drug support.
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX; and Josephine Ford Cancer Institute, Brownstown Charter Township, MI hkantarjian@mdanderson.org.
authors.forename: Hagop M
authors.initials: HM
authors.lastname: Kantarjian
authors.affiliation: The University of Texas MD Anderson Cancer Center, Houston, TX; and Josephine Ford Cancer Institute, Brownstown Charter Township, MI.
authors.forename: Robert
authors.initials: R
authors.lastname: Chapman
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D016527:Drug Costs / Q000331:legislation & jurisprudence / Q000639:trends*; D035082:Federal Government; D006273:Health Facility Merger / Q000639:trends; D006291:Health Policy; D006761:Hospitals / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*; D011203:Poverty; D011331:Private Practice / Q000639:trends*; D064876:Safety-net Providers / Q000639:trends*; D014481:United States; D035862:Vulnerable Populations
chemical_list: D000970:Antineoplastic Agents